TEPKINLY® (epcoritamab) is the first and only subcutaneous bispecific antibody approved as a monotherapy for adult patients with relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy
Conditional marketing authorization approval from the European Commission is supported by data from the pivotal Phase 1/2 EPCORE™ NHL-1 clinical trial
TEPKINLY represents AbbVie's second approved hematological cancer treatment in the European Union
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.